ICLR logo

ICON plc (ICLR)

$145.39

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ICLR

Market cap

$11.74B

EPS

7.4

P/E ratio

17.1

Price to sales

1.59

Dividend yield

--

Beta

1.269658

Price on ICLR

Previous close

$163.11

Today's open

$162.62

Day's range

$144.27 - $164.72

52 week range

$125.10 - $211.00

Profile about ICLR

CEO

Barry Balfe

Employees

39800

Headquarters

Dublin 18,

Exchange

Nasdaq Global Select

Shares outstanding

80756860

Issue type

American Depository Receipt

ICLR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ICLR

ICON's Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois. The new institute strengthens Accellacare's ability to support oncology clinical trials and broaden access to innovative cancer treatments for patients. The Brian Moran Cancer Institute includes: ‒ 14 medical oncologists ‒ Three radiation oncologi.

news source

Business Wire • Jan 27, 2026

news preview

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

news source

Seeking Alpha • Jan 27, 2026

news preview

ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC).

news source

Business Wire • Dec 9, 2025

news preview

ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines. The survey, conducted in June 2025 among just over 100 principal investigators and senior clinical trial site personnel, gathered per.

news source

Business Wire • Dec 2, 2025

news preview

ICON Public Limited Company (ICLR) Presents at Jefferies London Healthcare Conference 2025 Transcript

ICON Public Limited Company ( ICLR ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants Barry Balfe - CEO & Director Nigel Clerkin - Chief Financial Officer Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.

news source

Seeking Alpha • Nov 20, 2025

news preview

ICON plc to Present at the Jefferies London Healthcare Conference

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the Jefferies London Healthcare Conference.

news source

Business Wire • Nov 12, 2025

news preview

Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors

Invesco International Small-Mid Company Fund outperformed most in the real estate and consumer staples sectors due to stock selection. The fund's underweight in real estate also added to relative return. The fund underperformed most in healthcare, information technology and materials due to stock selection.

news source

Seeking Alpha • Nov 5, 2025

news preview

ICON Public Limited Company (ICLR) Q3 2025 Earnings Call Transcript

ICON Public Limited Company (NASDAQ:ICLR ) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants Kate Haven - Vice President of Investor Relations Steven Cutler Barry Balfe - CEO & Director Nigel Clerkin - Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michael Cherny - Leerink Partners LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Patrick Donnelly - Citigroup Inc., Research Division Jack Meehan - Nephron Research LLC Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Charles Rhyee - TD Cowen, Research Division Michael Ryskin - BofA Securities, Research Division David Windley - Jefferies LLC, Research Division Kyle Crews - UBS Investment Bank, Research Division Luke Sergott - Barclays Bank PLC, Research Division Christine Rains - William Blair & Company L.L.C.

news source

Seeking Alpha • Oct 23, 2025

news preview

ICON Reports Third Quarter 2025 Results

DUBLIN--(BUSINESS WIRE)--ICON Reports Third Quarter 2025 Results.

news source

Business Wire • Oct 22, 2025

news preview

Icon PLC (ICLR) Surpasses Q3 Earnings and Revenue Estimates

Icon PLC (ICLR) came out with quarterly earnings of $3.31 per share, beating the Zacks Consensus Estimate of $3.28 per share. This compares to earnings of $3.35 per share a year ago.

news source

Zacks Investment Research • Oct 22, 2025

news preview

¹ Disclosures

Get started with M1

Invest in ICON plc

Open an M1 investment account to buy and sell ICON plc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ICLR on M1